Featured Publications

Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives.

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

Nature Communications
February 2025

Vaccines for HPV-associated diseases

Molecular Aspects of Medicine
December 2023

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Laryngoscope
May 2023

HPV-Targeted

Title	Disease Target	Product
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses Science Translational Medicine — October 2012	Cervical Dysplasia	VGX-3100
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100 Molecular Therapy Oncolytics — January 2016	Cervical Dysplasia	VGX-3100
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy Clinical Cancer Research — January 2018	Cervical Dysplasia	VGX-3100
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis BMJ — July 2016	Cervical Dysplasia	VGX-3100
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis Vaccines — January 2020	RRP	INO-3107
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer Clinical Cancer Research — January 2019	Head & Neck Cancer	MEDI0457
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial The Lancet — September 2015	Cervical Dysplasia	VGX-3100
Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis Laryngoscope — May 2023	Recurrent Respiratory Papillomatosis	INO-3107
Vaccines for HPV-associated diseases Molecular Aspects of Medicine — December 2023	HPV-associated Diseases
DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107 Nature Communications — February 2025	RRP	INO-3107

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases